New Tel Aviv University study reveals 'Achilles' heel' of cancer cells

January 27, 2021

What makes cancer cells different from ordinary cells in our bodies? Can these differences be used to strike at them and paralyze their activity? Cancer researchers have been debating this question since the mid-19th century.

A new study from Tel Aviv University (TAU) shows, for the first time, how an abnormal number of chromosomes (aneuploidy) -- a unique characteristic of cancer cells that researchers have known about for decades -- could become a weak point for these cells. The study could lead to the development of future drugs that will use this vulnerability to eliminate the cancer cells.

The study was conducted in the laboratory of Dr. Uri Ben-David of TAU's Sackler Faculty of Medicine, in collaboration with six laboratories from four other countries. It was published in the journal Nature on January 27, 2021.

Aneuploidy is a hallmark of cancer. Normal human cells contain two sets of 23 chromosomes each, one from the father and one from the mother. But aneuploid cells have a different number of chromosomes. When aneuploidy forms in cancer cells, the cells not only "tolerate" it, but it can even advance the progression of the disease. The relationship between aneuploidy and cancer was discovered over a century ago, long before it was known that cancer was a genetic disease and even before the discovery of DNA as hereditary material.

According to Dr. Ben-David, aneuploidy is the most common genetic change in cancer. Approximately 90% of solid tumors, such as breast cancer and colon cancer, and 75% of blood cancers are aneuploid in nature. But researchers' understanding of the how aneuploidy contributes to the development and spread of cancer has been limited.

In the study, the researchers used advanced bioinformatics methods to quantify aneuploidy in approximately 1,000 cancer cell cultures. They then compared the genetic dependency and drug sensitivity of the cells with a high level of aneuploidy to those of the cells with a low level of aneuploidy.

They found that aneuploid cancer cells demonstrate heightened sensitivity to damage to the mitotic checkpoint - a cellular checkpoint that ensures the proper separation of chromosomes during cell division. They also discovered the molecular basis for the heightened sensitivity of aneuploid cancer cells.

The study has important implications for the drug discovery process in personalized cancer medicine. Drugs that delay the separation of chromosomes are undergoing clinical trials, but it is not known which patients will respond to them and which will not. The results of this study suggest that it will be possible to use aneuploidy as a biological marker to identify patients who will respond better to these drugs.

"It should be emphasized that the study was done on cells in a culture and not on cancer patients. In order to translate it to treatment of cancer patients, many more follow-up studies must be performed. Still, even at this stage it is clear that the study could have a number of medical implications," Dr. Ben-David says.
-end-
ABOUT TEL AVIV UNIVERSITY

Tel Aviv University (TAU) exemplifies the qualities of the city it inhabits -- innovative, fast-paced, exciting, and creative. A globally top-ranked university, a leading research institution, a center of discovery -- TAU embraces a culture and student body that is inquisitive and responsive to pressing issues and world-wide problems. As Israel's largest public institution of higher learning, TAU is home to 30,000 students, including 2,100 international students from over 100 countries. The University encompasses nine faculties, 35 schools, 400 labs, and has 17 affiliated hospitals in its network.

American Friends of Tel Aviv University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.